What is claimed is:

1. A compound of Formula III:



III

or a pharmaceutically acceptable salt thereof, wherein:
W is CH_2 or NH;
R is optionally substituted C_{1-8} alkyl, halogen, optionally substituted C_{1-4} alkoxy, cyano, hydroxy, optionally substituted trifluoromethyl, or C_{1-4} thioalkoxy;
n is 0, 1, 2, or 3, with the proviso that R may be the same or different when n is 2 or 3; and
R_1 and R_2 can be the same or different and are independently selected from the group consisting of hydrogen, optionally substituted C_{1-8} alkyl, optionally substituted amide, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, and optionally substituted C_{3-7} cycloalkyl;
or R_1 and R_2 can be joined to form a 5 to 7-membered heterocycle optionally substituted with alkyl or aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.

2. The compound of claim 1, wherein R_1 and R_2 are hydrogen.

3. The compound of claim 1, wherein n is 0.

4. The compound of claim 1, having Formula IIIa:



IIIa

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4, which is compound 1 or 2:



1



2

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1, having Formula IVa:



IVa

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 6, which is compound 3 or 4:



3



4

or a pharmaceutically acceptable salt thereof

8. A compound of Formula V:



V

or a pharmaceutically acceptable salt thereof, wherein:

Z is O or S;

Y is C=O, C=S, or SO_2;

R is optionally substituted C_{1-8} alkyl, halogen, optionally substituted C_{1-4} alkoxy, cyano, hydroxy, optionally substituted trifluoromethyl, or C_{1-4} thioalkoxy;

n is 0, 1, 2, or 3, with the proviso that R may be the same or different when n is 2 or 3; and

R_1 and R_2 can be the same or different and are independently selected from the group consisting of hydrogen, optionally substituted C_{1-8} alkyl, optionally substituted amide, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, and optionally substituted C_{3-7} cycloalkyl;

or R_1 and R_2 can be joined to form a 5 to 7-membered heterocycle optionally substituted with alkyl or aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom;

wherein when Y is C=O, Z is not O.

9. The compound of claim 8, wherein R_1 and R_2 are hydrogen.

10. The compound of claim 8, wherein n is 0.

11. The compound of claim 8, having Formula Va:



Va

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 11, which is compound 5, 6, or 7:



5



6



7

or a pharmaceutically acceptable salt thereof

13. The compound of claim 8, having Formula VIa:



VIa

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 13, which is compound 8, 9, or 10:



8



9



10

or a pharmaceutically acceptable salt thereof.

15. The compound of any one of claims 1-14, which is the hydrochloride salt.

16. A composition comprising the compound of any one of claims 1-15.

17. A pharmaceutical composition comprising the compound of any one of claims 1-15 and a pharmaceutically acceptable carrier.

18. The composition of claim 16 or 17, wherein the composition is a dosage form, optionally an immediate release oral dosage form, optionally a tablet or a capsule.

19. A kit comprising the compound of any one of claims 1-15.

20. Use of the compound of any one of claims 1 -15 in the manufacture of a medicament for treating a disorder or condition selected from narcolepsy, cataplexy, excessive daytime sleepiness, obstructive sleep apnea, idiopathic hypersomnia, drug addiction, sexual dysfunction, fatigue, fibromyalgia, attention deficit/hyperactivity disorder, restless legs syndrome, depression, bipolar disorder, atypical depression, binge eating disorder, or obesity in a subject in need thereof, or promoting smoking cessation in a subject in need thereof.

21. The use of claim 20, wherein the disorder or condition is selected from narcolepsy, cataplexy, excessive daytime sleepiness, obstructive sleep apnea, and idiopathic hypersomnia.

22. The use of claim 21, wherein the excessive daytime sleepiness is associated with idiopathic hypersomnia, obstructive sleep apnea, multiple sclerosis, atypical depression, or drug-associated excessive sleepiness.

23. The use of any one of claims 20-22, comprising a composition comprising the compound, optionally a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier, to be administered.

24. The use of claim 23, wherein the composition is a dosage form, optionally an immediate release oral dosage form, optionally a tablet or a capsule.

25. The use of any one of claims 20-24, further comprising an additional therapeutic agent to be administered.